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Abstract
Background: The anti-infective agent Taurolidine (TRD) has been shown to have cell death inducing properties,
but the mechanism of its action is largely unknown. The aim of this study was to identify potential common target
genes modulated at the transcriptional level following TRD treatment in tumour cell lines originating from different
cancer types.
Methods: Five different malignant cell lines (HT29, Chang Liver, HT1080, AsPC-1 and BxPC-3) were incubated with
TRD (100 μM, 250 μM and 1000 μM). Proliferation after 8 h and cell viability after 24 h were analyzed by BrdU assay
and FACS analysis, respectively. Gene expression analyses were carried out using the Agilent -microarray platform to
indentify genes which displayed conjoint regulation following the addition of TRD in all cell lines. Candidate genes
were subjected to Ingenuity Pathways Analysis and selected genes were validated by qRT-PCR and Western Blot.
Results: TRD 250 μM caused a significant inhibition of proliferation as well as apoptotic cell death in all cell lines.
Among cell death associated genes with the strongest regulation in gene expression, we identified pro-apoptotic
transcription factors (EGR1, ATF3) as well as genes involved in the ER stress response (PPP1R15A), in ubiquitination
(TRAF6) and mitochondrial apoptotic pathways (PMAIP1).
Conclusions: This is the first conjoint analysis of potential target genes of TRD which was performed
simultaneously in different malignant cell lines. The results indicate that TRD might be involved in different signal
transduction pathways leading to apoptosis.
Background
Taurolidine (TRD) - a derivate of the aminosulfoacid
Taurin - has been clinically used for many years in peri-
tonitis and catheter related blood stream infections due
to its anti-microbial and anti-inflammatory properties
[1-3]. Recently it has been shown, that TRD also exerts
anti-proliferative and anti-neoplastic activity in vitro as
well as in vivo [4,5]. TRD has been reported to inhibit
proliferation and to induce programmed cell death in a
variety of cell lines derived from malignant tumours e.g.
glioblastoma [6,7], melanoma [8,9], mesothelioma
[10,11], colon carcinoma [12,13], squamous cell oeso-
phageal carcinoma [14] and sarcoma [15,16]. Recently,
favourable pharmacokinetic and safety data for TRD
have been reported following systemic application in
healthy volunteers [17] as well as in patients with locally
advanced gastric carcinoma and glioblastoma [18-20].
However, cell death inducing mechanisms of TRD
remain to be fully elucidated. Both the mitochondrial
dependent pathway [7,10,21-23] as well as the death
receptor associated pathways have been reported for
TRD [24,25,16,14]. Since the majority of information
about TRD effects is provided from studies with one sin-
gle cell line, there is a lack of a comprehensive view
across several cell lines of different malignancies. So far,
only two publications have addressed the changes in gene
expression following TRD exposure to malignant cells
using cDNA microarray techniques [14,16]. The aim of
this study was therefore, to analyse gene expression by
microarray analyses simultaneously in different malignant
cell lines - to identify potential TRD target genes which
displayed conjoint regulation in all cell lines.
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Cell lines and culture conditions
Five different human neoplastic cancer cell lines were
used for this experiment: HT29 colon carcinoma (CLS
Cell Lines Service, Eppelheim, Germany), Chang Liver
(HeLa contaminant, CLS Cell Lines Service, Eppelheim,
Germany), HT1080 fibrosarcoma (ATCC - LGC Stan-
dards GmbH, Wesel, Germany), AsPC-1 pancreas carci-
noma (CLS Cell Lines Service, Eppelheim, Germany)
and BxPC-3 pancreas carcinoma (ATCC - LGC Stan-
dards GmbH, Wesel, Germany). Chang Liver cells were
maintained with Dulbecco’s Modified Eagle Medium
(DMEM) - Hams’s F12, whereas HT1080 cells were cul-
tured in modified Eagle’s medium (MEM). The remain-
ing cell lines (HT29, AsPC-1, BxPC-3) were maintained
in RPMI 1640 (Biowest, Nuaille, France). All cultures
were supplemented with 10% fetal bovine serum, sup-
plemented with penicillin (100 U/ml), streptomycin (100
μg/ml) and 2 mM L-Glutamine (Biowest, Nuaille,
France). AsPC-1 and HT1080 cells were further supple-
mented with 1 mM Sodium Pyruvate. Cells were grown
as subconfluent monolayer and cultured in 25 cm
2 flasks
at 37°C and 5% CO2 in a humidified atmosphere.
Reagents
TRD (Taurolin®) ultrapure powder (kindly provided by
Geistlich Pharma AG, Wolhusen, Switzerland) was dis-
solved in a Povidon 5% solution (K16 Povidon, gener-
ously provided by Geistlich Pharma AG, Wolhusen,
Switzerland) and sterile filtered to achieve the respective
TRD concentrations. A Povidon 5% solution in equal
volume served as a control for TRD treatment.
BrdU proliferation assay
Cells were seeded to a density of 3 × 10
6 cells/well in 6-
well plates (growth area 9.6 cm
2/well) and incubated for
18-24 hours under the above mentioned culture condi-
tions to obtain a subconfluent monolayer. Subsequently,
cells were washed and incubated for another 2 hours
before reagents were added to the culture medium. To
examine the dose-response of TRD regarding its anti-
proliferative activity, cells were incubated with increas-
ing concentrations of TRD (100 μM, 250 μM, and 1000
μM) and Povidon 5% as control for 8 h and submitted
to BrdU proliferation assay (5-bromo-2’-deoxyuridine)-
ELISA (Roche Applied Science, Mannheim, Germany)
according to the manufacturer’s instructions. Our group
has recently shown, that the TRD concentration range
applied in this experiment (100 μM, 250 μM and 1000
μM) is suitable for examining anti-neoplastic activity in
these five cell lines [26]. Based on the incorporation of
the thymidine analogue BrdU during DNA synthesis,
the amount of newly synthesised DNA and thus of pro-
liferation cells is detected using a microplate absorbance
reader Sunrise™ (Tecan trading AG, Switzerland) after
applying anti-BrdU conjugated with peroxidase and
enhancing a specific substrate reaction. BrdU assays
were performed with 8 replicates of three independent
experiments with consecutive passages. The incubation
time of 8 h has been shwon to be appropriate for the
BrdU proliferation assay in previous experiments (data
not shown).
Flow Cytometry Analysis
All five cell lines were incubated for 24 h with TRD 250
μM and Povidon 5% as control and submitted to FACS
analysis. Our group has recently shown, that TRD 250
μM is sufficient to induce cell death in the respective cell
lines [26]. However, for the current study, FACS analysis
for this particular concentration (250 μM) was performed
in 9-11 independent experiments with 4-5 consecutive
passages. In brief, floating cells were collected together
with the supernatant and adherent cells were harvested
by trypsinisation. Cells were sedimented by centrifuga-
tion, resuspended and fixed in 195 μl binding buffer
(Bender MedSystems, Vienna, Austria). Cell density in
the cell suspension was adjusted to 2 × 10
3 cells/μl. Sub-
sequently, 5 μl Annexin V-FITC (BD Biosciences, Heidel-
berg, Germany) was added to the cell suspension
followed by gently vortexing and incubation for 10 min
at room temperature in the dark. Thereafter, the cell sus-
pension was centrifuged followed by resuspension in 190
μl binding buffer before 10 μl Propidiumiodide (Bender
MedSystems, Vienna, Austria) was added. Cells were ana-
lyzed immediately using a FACS (fluorescence activated
cell sorting) flow cytometer (FACS Calibur BD Bios-
ciences, Heidelberg, Germany) for Annexin V-FITC and
PI binding. For each measurement, 20.000 cells were
counted. Dot plots and histograms were analyzed by Cell-
Quest Pro software (BD Biosciences, Heidelberg, Ger-
many). Annexin V positive cells were considered
apoptotic; Annexin V and PI positive cells were identified
as necrotic. Annexin V and PI negative cells were termed
viable. All experiments were repeated 9-11 times with 4-
5 consecutive passages. The incubation time of 24 h has
been shwon to be appropriate for the FACS analysis in
previous experiments lines [26].
cDNA microarray analysis
Total RNA was purified from the cells after incubation
with the different substances (Povidon 5%; TRD 100
μM, 250 μM and 1000 μM) for 6 h using the RNeasy
KIT from Qiagen (Hilden, Germany), as specified by the
manufacturer. RNA integrity was assessed using stan-
dard denaturing agarose gel electrophoresis. For micro-
array analyses, we used the Agilent Array platform
employing the manufacturer’s standard protocols for
sample preparation and microarray hybridization.
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amplified and transcribed into fluorescent cRNA follow-
ing the manufacturer’s Quick Amp Labeling protocol
(Version 5.7, Agilent Technologies). Since we aimed at
an intensity-based analysis of the two-colour microar-
rays as suggested by ‘t Hoen et al. [27], RNA samples
from individual series of analyses comprising of RNAs
derived from one specific cell line under the various
TRD treatments and control conditions (Povidon 5%)
were either Cy-5 (HT29, Chang Liver and HT1080) or
Cy-3 (BxPC3, AsPC1) labelled. Labelled samples were
hybridized towards the Whole Genome Oligo Array (4
× 44 Kk, product no. G4412T; Agilent Technologies)
and following the washing steps the arrays were scanned
using the Agilent Scanner G2505B. Agilent’s Feature
Extraction software 10.7.3.1 (Feature Extraction Protocol
GE2_ 105-Dec08) was used to analyze acquired array
images. Subsequent data processing was performed
using the GeneSpringGX11.01 software package (Agilent
Technologies). Following quantile normalization of the
raw data, data sets were further reduced by filtering the
raw signal intensity value to ≥50 in at least one out of
the 20 samples analyzed. A one-way ANOVA model fol-
lowed by Tukey’s HSD (Honestly Significant Difference)
test was used to test the hypothesis that there was no
difference in expression between the TRD treatment
group and the Povidon control group and multiplicity
correction (Benjamini-Hochberg) was included to con-
t r o lt h ef a l s ed i s c o v e r yr a t e( F D R )a t0 . 0 5 % .I nap a i r -
wise comparison for differentially expressed genes iden-
tified between POV and TRD 250 μM treated cell lines
by ANOVA a subset of genes was identified that dis-
played a conjoint regulation in all five cell lines after
TRD 250 μM treatment with a mean increase or
decrease ≥ 2 fold compared to control treatment (Povi-
don 5%). This subset of genes was subjected to Ingenu-
ity Pathways Analysis (Ingenuity® Systems, Redwood
City, CA, USA). Genes associated with biological func-
tions in Ingenuity’s Knowledge Base were considered for
the analysis. Right-tailed Fisher’se x a c tt e s tw a su s e dt o
calculate a p-value determining the probability that each
biological function assigned to that data set is due to
chance alone.
Real-time PCR for microarray data validation
Microarray data validation was performed for the
selected candidate genes ATF3, GADD34, TRAF6,
PMAIP1 as well as EGR1 for TRD 250 μM and Povidon
5% as control. Total RNA (2 μg) was reverse transcribed
using the High Capacity cDNA Archive Kit (Applied
Biosystems). RNA isolation was performed from cells
harvested after 6 h following treatment. cDNA was
synthesized using 2 μg of total RNA, oligo(dT)18 primers
and 200 U of MMLV reverse transcriptase (Promega,
Mannheim, Germany) following the manufacturer’s pro-
tocol. qRT-PCR was performed using a SYBR Green I
reaction mixture containing 75 mM Tris-HCl (pH 8.8),
20 mM ammonium sulfate, 0.01% (v/v) Tween 20, 2
mM magnesium chloride (all Sigma-Aldrich, Munich,
Germany), 1 μl of a 600-fold dilution of SYBR Green I
(BioWhittaker, Rockland, ME, USA), 2.5 U Taq poly-
merase (NEB, Frankfurt a.M., Germany), 0.2 mM dNTP
(Promega, Mannheim, Germany) and 0.2 μM of forward
and reverse primer (QIAgen, Hilden, Germany) in a
final reaction volume of 20 μl. Reactions were run on a
DNA Engine Opticon®2 cycler (MJ Research, Waltham,
MA, USA). The cycling conditions consisted of 3 min
initial denaturation at 94°C and 40 cycles of 94°C for 30
sec, 60°C for 30 sec, 72°C for 30 sec and 80°C for 3 sec.
Fluorescence was measured at the last step of each
cycle. Melting curves were obtained after each PCR run
a n ds h o w e ds i n g l eP C Rp r o d u c t s .c D N A sw e r er u ni n
duplicates, including non-RT (without reverse transcrip-
tase) and no-template controls. PCR efficiencies were
determined using serial dilutions of a cDNA derived
from a cell line. Expression levels for genes of interest
and for housekeeping genes were measured in indepen-
dent PCR runs. Expression ratios were calculated as
described by Pfaffl [28] including the geometric mean
expression of the housekeeping genes GAPD and PPIA
to normalize the expression data for the gene of interest.
Primers used are available through the authors upon
request.
Western Blot
To validate the findings of changed gene expression on
protein level, Western Blots were performed for selected
target genes whenever appropriate antibodies were avail-
able. Total protein was purified from the cells after
incubation for 8 h with Taurolidine 250 μMa n dP o v i -
don 5% as control treatment. For this purpose floating
cells were collected together with the supernatant and
sedimented by centrifugation. After removal of the
supernatant, adherent cells were added after harvesting
with a cell scrapper and Cell Culture Lysis Reagent
(Promega Corporation, Mannheim, Germany). Probes
were incubated with a total amount of 50 μlC e l lC u l -
ture Lysis Reagent (Promega Corporation, Mannheim,
Germany) each for 1 h on ice. The cell remnants were
sedimented by centrifugation leading to supernatants
containing the purified protein. Protein concentration in
each sample was determined using a Micro BCA protein
assay kit (Pierce, Rockford, IL, USA). Aliquots that con-
tained equal amount of total proteins from each sample
were separated in SDS-polyacrylamide gels and electro-
phoretically transferred onto PVDF membranes (Bio-
Rad Laboratories, Munich, Germany), which were subse-
quently probed for 1 h - 3 h at room temperature with
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(Santa Cruz Biotechnology, Heidelberg, Germany). Blots
were further incubated for 1 h with secondary horserad-
ish peroxidase (HRP)-conjugated anti-rabbit IgG (GE
Healthcare, Little Chalfont, UK), and then developed
using an enhanced chemiluminescence detection system
(ECL Plus Western Blotting Detection System, GE
Healthcare, Little Chalfont, UK) according to the manu-
facturers’ instructions. After finishing the western blot
for the respective target genes, each membrane was
stripped with stripping buffer (100 mM NaOH, 2% SDS,
0.5% DTT, 1 h for 55C) and incubated with GAPDH
antibody (FL-335) (Santa Cruz Biotechnology, Heidel-
berg, Germany) as loading control.
Statistical analysis
Results of FACS-analysis (percentage of viable, apoptotic
and necrotic cells) as well as results of BrdU assay (per-
centage of proliferating cells) are expressed as means ±
SEM. Comparison between experimental groups (con-
trol, TRD 100 μM, TRD 250 μMa n dT R D1 0 0 0μM)
was performed using one-way ANOVA followed by
Tukey’s post-hoc test. P-values ≤ 0.05 were considered
as statistically significant and indicated in the figures as
follows: *** p ≤ 0.001, ** p ≤ 0.01, * p ≤ 0.05.
Results
TRD uniformly inhibits proliferation of all cell lines in a
dose dependent manner
As indicated in figure 1, incubation with TRD in
increasing concentrations (100 μM, 250 μM and 1000
μM) for 8 hours resulted in an dose dependent reduc-
tion of proliferating cells - as measured by BrdU assay.
In all cell lines except HT29, even the lowest TRD con-
centration (100 μM) was capable of inhibiting prolifera-
tion leading to values of proliferating cells ranging
between 53.4% (± 11.0%) (Chang Liver) and 93.8% (±
8.1%) (BxPC-3) which was significantly lower compared
to untreated controls (100%) (Povidon 5%) (figure 1).
However, the following TRD concentration of 250 μM
significantly inhibited proliferation in all five cell lines.
The pronounced inhibition mediated by TRD 250 μM
resulted in values of proliferating cells between 12.7% (±
0.56%) for Chang liver and 56.1% (±11.7) for HT29 (fig-
ure 1a-b). The maximal dose of 1000 μM led to further
inhibition of proliferation in all cell lines. As a result,
dose response for cell proliferation was proportional in
all cell lines (figure 1).
TRD induces apoptotic cell death in all cell lines at a
concentration of 250 μM
As summarized in figure 2, incubation of the five cell
lines with TRD 250 μM for 24 hours resulted in a sig-
nificant reduction of viable cells compared to control
treatment with Povidon 5% as evaluated by FACS analy-
sis for Annexin V-FITC and PI. The TRD concentration
of 250 μM was choosen in this experiment, since we
could previously show that TRD 250 μM was the lowest
among several concentrations (100 μM, 250 μMa n d
1000 μM) that significantly inhibited cell viability in all
cell lines [26]. Furthermore, TRD 250 μMw a st h el o w -
est concentration that significantly inhibited prolifera-
tion in all cell lines as measured by BrdU assay (figure
1). As shown in figure 2a, cell viability following incuba-
tion with TRD 250 μM was varying between 69.5% (±
3.2%) for HT29 and 35.7% (± 1.7%) for Chang Liver
cells. The significant reduction of cell viability by TRD
250 M was paralleled by a significant increase of apop-
totic cells in all cell lines (figure 2b). The apoptotic
effect was ranging between 20.1% (± 1.5%) for BxPC-3
and 31.0% (± 2.4%) for AsPC-1) (figure 2b). Addition-
ally, there was also a significant increase in necrosis in
Chang Liver, HT1080 and BxPC-3 cells (figure 2c).
Representative dot plots obtained by FACS analysis for
incubation with TRD 250 μM and control treatment
(Povidon 5%) in the five respective cell lines are pre-
sented in figure 3.
TRD 250 μM leads to conjoint regulation of different
genes in all five malignant cell lines
In order to answer the question whether TRD treatment
may modulate signalling pathways common in several
different tumour types rather than being tumour cell
type specific we subjected the above described different
cell lines (HT29 (colon), Chang Liver (liver), HT1080
(fibrosarcoma), AsPC-1, BxPC-3 (both pancreas)) to glo-
bal gene expression analyses using Agilent microarray
technology. A comparison of the expression profiles in
the TRD treatment (250 μM) vs. control treatment
(Povidon 5%) revealed 592 probe sets that were signifi-
cantly up- or down regulated in all five cell lines with a
mean change ≥ 2 fold compared to the control treat-
ment group (additional file 1, table S1). A total of 450
probe sets were significantly down-regulated in all cell
lines with a mean decrease of 3.1 fold (95% CI 2.97 -
3.18) from control treatment to TRD 250 μM treatment.
The remaining 142 genes were up-regulated with a
mean increase of 7.3 fold (95% CI 6.97 - 7.72) from con-
trol treatment to TRD 250 μM treatment. From these
genes we identified the top high-level functions by Inge-
nuity global function analysis (p < 0.05). 55 genes out of
592 probe sets were associated with at least one of the
three functions “Cell Death”, “Cell Growth and Prolif-
eration”,a n d“Cell Cycle” (figure 4). The function “Cell
Death” was most frequent and associated with 36 genes,
followed by “Cell Cycle (29 genes) and “Cell Growth and
Proliferation” (29 genes) (figure 4) (additional file 1,
table S1). The distribution and overlapping of target
Chromik et al. BMC Cancer 2010, 10:595
http://www.biomedcentral.com/1471-2407/10/595
Page 4 of 13genes within the three functions is illustrated in figure 4.
Potential TRD regulated genes common to all five cell
lines that increased or decreased ≥ 4f o l da n dt h a tw e r e
identified by Ingenuity Pathways Analysis are further
summarized in table 1. There was a striking up-regulation
of several transcription factors (TFs) like EGR1, ATF3,
F O S B ,F O S ,S N A I 1 ,N R A 2a n dH E S 1 .O t h e rg r o u p so f
genes comprised cell cycle regulators (GADD45A,
Figure 1 Effects of Taurolidine (TRD) on proliferation in different malignant cell lines measured by BrdU-assay. HT29 (a), Chang Liver (b),
HT1080 (c), AsPC-1 (d) and BxPC-3 cells (e) were incubated with TRD (100 μM, 250 μM and 1000 μM) and with Povidon 5% (control) for 8 h and
submitted to a BrdU-assay. Values are means ± SEM of 8 replicates of three independent experiments with consecutive passages. Asterisk
symbols on columns indicate differences between control, which was set to 100% and TRD treatment. Asterisk symbols on brackets indicate
differences between TRD groups. *** p ≤ 0.001, ** p ≤ 0.01, * p ≤ 0.05 (one-way ANOVA followed by Tukey’s post-hoc test)
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in the ubiquitin pathway (UBE2B, TRAF6), the endoplas-
mic reticulum response (PPP1R15A), the mitochondrial
apoptotic pathway (PMAIP1) or the death receptor path-
w a y( F A D D )( t a b l e1 ) .T h ec o m p l e t em i c r o a r r a yd a t af o r
all probe sets with the respective normalised values (all
cell lines, Povidon 5%, TRD 100 μM, TRD 250 μM, TRD
1000 μM) are provided in additional file 2, table S2.
Confirmation of altered gene expression following TRD
250 μM incubation by qRT-PCR and western blot
Messenger RNA expression of five selected TRD regu-
lated genes was examined by quantitative real-time RT-
PCR in all cell lines (figure 5). The gene with the stron-
gest regulation during microarray analysis was EGR1
(Early growth response 1) with a mean fold change (FC)
of 45.9 (table 1) which belongs to the EGR zinc-finger
family of TFs [29] and is known to have anti-neoplastic
activity [30]. This intensive induction could be con-
firmed by qRT-PCR, which revealed an up-regulation
ranging from 8-fold to 145-fold (figure 5a). The second
strongest regulation observed in the microarray analysis
was referred to ATF3 (Activating transcription factor 3)
(mean FC of 39.9) (table 1). ATF 3 is a member of the
CREB family of transcription factors and is activated by
various stimuli [31]. This result could also be confirmed
by qRT-PCR, which resulted in a 4-fold to 48-fold
increase (figure 5b). Two genes of special interest were
also validated by qRT-PCR: PPP1R15A (Protein phos-
phatase 1, regulatory (inhibitory) subunit 15A; syn.
GADD34), representing an important protein phospha-
tase involved in cell death pathways [32,33] as well as
PMAIP1 (Phorbol-12-myristate-13-acetate-induced pro-
tein 1; syn. NOXA), a pro-apoptotic mitochondrial pro-
tein of the Bcl-2 family, which is known to be involved
in the intrinsic mitochondrial apoptotic pathway [34].
Although the expressional changes in microarray experi-
ments were lower than for the two other validated genes
(mean FC of 9.0 and 10.2, respectively), comparable
results could be obtained by qRT-PCR for PPP1R15A
( 3 - f o l dt o1 8f o l di n c r e a s e )a n dP M A I P 1( 2f o l dt o1 0
fold increase) (figure 5c+d). TRAF6 (TNF receptor asso-
ciated factor 6), a member of the E3 ubiquitin ligase
family which can specificly target different proteins for
Lys63 ubiquitination [35,36] was significantly down-
regulated both in microarray analysis (mean FC of 4.8)
and in qRT-PCR (5 to 9 fold decrease) (figure 5e). To
further confirm altered gene expression of potential
TRD target genes, western blots were performed when
appropriate antibodies were available. As indicated in
figure 6a, all cell lines displayed a pronounced upregula-
tion of ATF3 protein, which was mirrored by the gene
expression data as previously mentioned. PPP1R15A was
also expressional regulated on protein level (figure 6b).
Figure 2 Effects of Taurolidine (TRD) 250 μM on viability,
apoptosis and necrosis in different malignant cell lines. HT29,
Chang Liver, HT1080, AsPC-1 and BxPC-3 cells were incubated with
TRD 250 μM and with Povidon 5% (control) for 24 h. The
percentages of viable (a), apoptotic (b) and necrotic cells (c) were
determined by FACS-analysis for Annexin V-FITC and
Propidiumiodide. Values are means ± SEM of 9 (HT29), 10 (Chang
Liver, BxPC-3) or 11 (HT1080, AsPC-1) independent experiments with
4-5 consecutive passages. Asterisk symbols on columns indicate
differences between control and TRD treatment. *** p ≤ 0.001, ** p
≤ 0.01, * p ≤ 0.05 (one-way ANOVA followed by Tukey’s post-hoc
test)
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Page 6 of 13Figure 3 Representative dot plots obtained by FACS analysis after incubation of different cell lines with Taurolidine. HT29, Chang Liver,
HT1080, AsPC-1 and BxPC-3 cells were incubated with Taurolidine (TRD) 250 μM and with Povidon 5% (control) for 24 h. FACS analysis was
performed for Annexin V-FITC (x-axis) and Propidiumiodide (y-axis). Lower left quadrant: Annexin V and Propidiumiodide negative (viable cells),
lower right quadrant: (Annexin V positive and Propidiumiodide negative (apoptotic cells), upper right quadrant: Annexin V and Propidiumiodide
positive (necrotic cells).
Figure 4 Venn diagram for 55 genes identified by Ingenuity Pathways Analysis®. Ingenuity Pathways Analysis identified 55 Taurolidine
regulated genes - in all five cell lines - to be involved in “Cell death”, “Cell growth and proliferation” and “Cell cycle” function. The 55 genes were
significantly up- or down regulated in all five cell lines with a mean change ≥ 2 fold following Taurolidine (250 μM) treatment compared to
control treatment (Povidon 5%). The Venn diagram illustrates the distribution and overlapping of Taurolidine regulated genes among the
different functions.
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vincing increase in PPP1R15A protein (figure 6b), which
was also less pronounced on mRNA level (figure 5c).
Discussion
Taurolidine (TRD) represents an interesting anti-neo-
plastic agent with a potential perspective in oncologic
pharmacotherapy. Although it has already been intrave-
nously applied to patients with advanced gastric cancer
[18] and glioblastoma during pilot studies with promis-
ing results [19,18], the mechanisms of action remains to
be elucidated in detail [4,5]. Microarray technology
offers a powerful tool for investigating the cellular
responses to anti-neoplastic substances like TRD
because it monitors thousands of genes simultaneously.
Although two recent publications from our group have
already focussed on microarray derived transcriptional
profiling of TRD treatment in two single cell lines
[16,14], the current project provides the first microarray
analysis which was performed simultaneously in five dif-
ferent and heterogeneous cell lines of four different
malignancies to identify potential common TRD target
genes.
Microarray experiments were focussed on a TRD con-
centration of 250 μM. We have recently shown in a study
analysing TRD effects by FACS analysis in five cell lines
identical with the current study (HT29, Chang Liver,
HT1080, AsPC-1 and BxPC-3) that TRD inhibits cell via-
bility over a broad range of concentrations (100 μM, 250
μM and 1000 μM) [26]. In the latter study, TRD 250 μM
was the lowest concentration that significantly inhibited
cell viability in all cell lines [26]. This fact is now sup-
ported by the current study, since TRD 250 μMs i g n i f i -
cantly induced apoptotic cell death in our experiments -
as measured by FACS analysis (figure 2+3). Furthermore,
TRD 250 μM was the lowest concentration that signifi-
cantly inhibited proliferation in all cell lines as measured
by BrdU assay (figure 1). The effectiveness of TRD 250
μM as powerful anti-neoplastic concentration in cell cul-
ture experiments is consistent with several studies that
evaluated the anti-proliferative and cell death inducing
activity of TRD over a broad range of concentrations (50
μM - 2000 μM) in different cell lines using proliferation
assays [37,38,11,39,10,16] or quantitative FACS analysis
[16,14,13,11]. As indicated in figure 1 and 2, our results
showed quite distinct and cell line specific differences in
Table 1 Microarray results with characteristics of 21 genes regulated by Taurolidine identified by Ingenuity pathway
analysis
Probe Set Acession
code
Gene
symbol
Gene name FC Dir Con TRD CD CG CC
A_23_P214080 NM_001964 EGR1 Homo sapiens early growth response 1 45,9 ⇑ 7,7 13,2 1 1 1
A_23_P34915 NM_004024 ATF3 Homo sapiens activating transcription factor 3 39,9 ⇑ 8,8 14,1 0 1 1
A_23_P429998 NM_006732 FOSB FBJ murine osteosarcoma viral oncogene homolog B 38,7 ⇑ 5,8 11,0 1 0 0
A_23_P106194 NM_005252 FOS v-fos FBJ murine osteosarcoma viral oncogene homolog 28,4 ⇑ 7,6 12,4 1 1 1
A_23_P131846 NM_005985 SNAI1 snail homolog 1 27,6 ⇑ 7,4 12,2 1 0 0
A_24_P239606 NM_015675 GADD45B growth arrest and DNA-damage-inducible, beta 16,0 ⇑ 10,5 14,5 1 1 1
A_23_P207999 NM_021127 PMAIP1 phorbol-12-myristate-13-acetate-induced protein 1 = NOXA 10,2 ⇑ 8,0 11,3 1 0 0
A_23_P23221 NM_001924 GADD45A growth arrest and DNA-damage-inducible, alpha 10,1 ⇑ 10,3 13,7 1 1 1
A_23_P131208 NM_006186 NR4A2 nuclear receptor subfamily 4, group A, member 2 9,2 ⇑ 5,3 9,0 1 0 1
A_23_P90172 NM_014330 PPP1R15A protein phosphatase 1, regulatory (inhibitor) subunit 15A =
GADD34
9,0 ⇑ 8,4 11,5 1 1 1
A_23_P436259 NM_152461 ERN1 endoplasmic reticulum to nucleus signalling 1 = IRE1 8,3 ⇑ 6,9 10,0 1 0 0
A_23_P218463 NM_013376 SERTAD1 SERTA domain containing 1 7,2 ⇑ 12,6 15,4 0 1 0
A_24_P921446 BC017854 EMP1 epithelial membrane protein 1 6,7 ⇑ 5,9 8,6 1 0 0
A_23_P385034 NM_001949 E2F3 E2F transcription factor 3 6,6 ⇓ 11,7 9,0 0 1 1
A_24_P278637 NM_003824 FADD Fas associated death domain 5,9 ⇓ 9,3 6,8 1 0 1
A_23_P362415 BC001694 UBE2B ubiquitin-conjugating enzyme E2B 5,7 ⇑ 4,5 7,0 1 0 1
A_24_P938293 NM_005524 HES1 hairy and enhancer of split 1 5,4 ⇑ 9,7 12,1 0 1 1
A_23_P75921 NM_145803 TRAF6 TNF receptor-associated factor 6 4,8 ⇓ 7,8 5,5 1 1 0
A_23_P408094 NM_002357 MXD1 MAX dimerization protein 1 4,7 ⇑ 6,7 8,9 1 0 1
A_23_P254179 NM_015339 ADNP activity-dependent neuroprotector 4,3 ⇓ 10,8 8,7 1 1 0
A_24_P360674 NM_078487 CDKN2B cyclin-dependent kinase inhibitor 2B 4,1 ⇑ 4,8 6,6 0 1 1
Microarray results with characteristics of 21 genes regulated by Taurolidine (TRD) 250 μM ≥ 4 fold compared to control treatment (Povidon 5%) which were
identified by Ingenuity pathway analysis. Abbreviations: FC = fold change, Dir = direction of changed expression (⇑ = increased or ⇓ = decreased expression
compared to control treatment), Con = mean normalised gene expression following control treatment (Povidon 5%), TRD = mean normalised gene expression
following Taurolidine 250 μM treatment (raw = raw values, norm = normalised values), CD = cell death, CG = cell growth and proliferation, CC = cell cycle
associated gene as analyzed by Ingenuity pathway analysis (1 = yes, 0 = no).
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Page 8 of 13susceptibility towards TRD induced cell death. One can
only speculate about the differences in the anti-neoplastic
activity of TRD. However, none of the cell lines tested in
our study was resistent to TRD induced cell death.
Using cRNA Microarray assay combined with Ingenu-
ity pathways analysis we identified several TRD regu-
lated genes that might represent potential target genes
for TRD in malignant cells. Among the 21 genes with ≥
4 fold expressional change (table 1), we focussed in our
validation experiments on 5 genes, that represent - in
our eyes - genes of special interest: the transcription fac-
tors (TFs) EGR1 and ATF3, the ER-stress response gene
PPP1R15A, the pro-apoptotic mitochondrial protein
PMAIP1 and the E3 ubiquitin ligase TRAF6. EGR1
Figure 5 Quantitative gene expression changes following Taurolidine treatment in five malignant cell lines. HT29, Chang Liver, HT1080,
AsPC-1 and BxPC-3 cells were incubated with Taurolidine (TRD) 250 μM and with Povidon 5% (control) for 6 h. For validation of altered gene
expression observed during microarray experiments, relative expression levels compared to the control (5% Povidon) were determined by qRT-
PCR for EGR1 (a), ATF3 (b), PPP1R15A (c), PMAIP1 (d) and TRAF6 (e).
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Page 9 of 13(early growth response 1) representing the gene exhibit-
ing the strongest induction upon TRD treatment was
confirmed by qRT-PCR. EGR1 belongs to the EGR zinc-
finger family of TFs [29] which can provide anti-neo-
plastic activity in numerous tumour cell lines by indu-
cing tumour suppressors like PTEN, TGFb1, p53,
fibronectin or ATF3 [40,30,41]. Furthermore, several
anti-neoplastic or chemopreventive agents have recently
been shown to target EGR1 expression and EGR1 driven
pathways in colorectal cancer [42-44]. Furthermore, our
microarray analyses revealed a strong up-regulation of
the pro-apoptotic transcription factor ATF3 (table 1),
whereas other EGR1 target genes with tumour suppres-
sor function like PTEN, TGFb1, p53 and fibronectin did
not show any significant regulation (additional file 2,
table S2). The common induction of of EGR1 and ATF3
expression in all lines tested might indicate that activa-
tion of the EGR1/ATF3 signalling axis is an important
mode of regulation how TRD mediates its growth sup-
pressive action and/or apoptosis induction. The impor-
tance of EGR1/ATF3 axis in death signalling is
supported by recent studies that described an EGR1 dri-
ven activation of the pro-apoptotic transcription factor
ATF3 in colorectal cancer cells following treatment with
anti-neoplastic substances [44,45]. ATF3 itself belongs
to the CREB family of transcription factors and is
regarded as a stress-inducible gene due to its activation
by variety of stimuli e.g. radiation [31], chemotherapeu-
tic agents [46,47] oxidative stress [48,49] or ER stress
[50]. Although the physiologic functions of ATF3 are
not well understood, there is some evidence that ATF3
functions as a pro-apoptotic gene in cancer cells. ATF3
has been shown to enhance the apoptotic effect of cur-
cumin in squamous cell carcinoma cells [51] and to
mediate nitric oxide-induced apoptosis in pancreatic
beta cells [52]. Furthermore, ATF3 has been shown to
promote UV induced apoptosis and cell cycle arrest in
fibroblasts by binding the promoter and repressing the
transcription of cyclin D1 -a key regulator of the G1-S
checkpoint [53]. We can only speculate about the TRD
driven stimulation of ATF3, but oxidative stress pro-
vides a possible pathway. Previous studies have pre-
sented first evidence for involvement of TRD mediated
reactive oxygen species (ROS) production in malignant
cells [7,25,26] and cell death induced by TRD has been
shown to be reversible by application of radical scaven-
gers like N-Acetylcysteine [7,54,25,10,26]. Another pos-
sible cell death associated pathway resulting in
activation of ATF3 by TRD is the ER stress response
pathway [55,56], since TRD has been reported to inhibit
protein translation in tumour cells at an early stage [37].
Together with the above mentioned production of ROS,
this might result in disturbance of ER homeostasis lead-
ing to ER stress response. Indicative of an involvement
of the ER stress response pathway, we identified two
g e n e st h a tw e r eu p - r e g u l a t e db yT R Da n dk n o w nt ob e
activated during ER stress, e.g. PPP1R15A (syn.
GADD34) and the above mentioned ATF3. PPP1R15A
represents an interesting potential TRD target gene,
since PPP1R15A confers both apoptotic signalling
[32,33] and inhibition of the translational silencing dur-
ing ER stress via binding the catalytic subunit of protein
phosphatase 1 leading to dephosphorylation of eIF2a
[57,58]. Another strongly TRD regulated gene is
PMAIP1 (syn. NOXA), a pro-apoptotic member of the
BH3-only protein family, which is known to be involved
in the intrinsic mitochondrial apoptotic pathway [34].
PMAIP1 exerts its pro-apoptotic function mainly by
neutralizing anti-apoptotic members of the Bcl2 family
through direct interaction, which has been proven for
Bcl-2 related protein A1 (BCL2A1) and myeloid cell leu-
kemia sequence 1 (MCL1) [59,60]. Interestingly, besides
Bcl-2 like protein 11 (BCL2L11), which was 3-fold
down-regulated, none of the remaining Bcl-2 family
Figure 6 Western blot analysis of selected genes targeted by Taurolidine treatment in five malignant cell lines. HT29, Chang Liver,
HT1080, AsPC-1 and BxPC-3 cells were incubated with Taurolidine (TRD) 250 μM and with Povidon 5% (control) for 8 h. Western blot analysis
was performed for validation of altered gene expression observed during microarray experiments for ATF3 (a) and PPP1R15A (b). GAPDH served
as loading control.
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Page 10 of 13members (including MCL1 and BCL2A1) revealed a sig-
nificant expressional change after TRD treatment in our
experiments (additional file 2, table S2). Among the
genes that were significantly down-regulated following
TRD treatment, TRAF6 was considered as an especially
important candidate gene. TRAF6 represents a member
of the TRAF family of proteins that is involved in both
the TNF receptor and the interleukin-1 receptor (IL-
1R)/Toll-like receptor (TLR) superfamily signal trans-
duction and is referred to innate and adaptive immunity,
bone metabolism and developmental pathways [61,62].
Recently it has been shown that TRAF6 possesses an
ubiquitin ligase activity domain (E3 ligase) that confers a
site specific (Lys63) ubiquitination of different target
proteins [35,36]. Interestingly, the protein kinase AKT -
activated and transmitting survival signals in many
tumours - has also been reported to be an ubiquitina-
tion target of TRAF6. Ubiquitination of AKT by TRAF6
is essential for its membrane recruitment and phosphor-
ylation following growth factor activation [63]. Further-
more, inhibition of AKT phosphorylation has been
described following TRD application in mesothelioma
cells [11]. Although we did not find significant changes
in the expression of AKT (additional file 2, table S2)
and did not analyse AKT phosphorylation, the reduced
expression of TRAF6 in our experiments provides a
potential hint to the inhibition of the oncogenic AKT
pathway by TRD. However, the involvement of the
above mentioned pathways in TRD mediated cell death
has to be addressed in further studies.
Conclusions
This study provides the first identification of potential
common target genes modulated by TRD treatment of
cell lines originating from four different cancer types.
Among the TRD regulated genes, we identified pro-
apoptotic transcription factors, cell cycle regulators and
proteins involved in ubiquitination, endoplasmic reticu-
lum response and mitochondrial apoptotic pathways.
Our results indicate that TRD is involved in different
signal transduction pathways leading to multifaceted cell
death mechanisms. Further studies are necessary to
address the potential target genes in functional assays.
Additional material
Additional file 1: Probe sets that were significantly up- or down
regulated in all five cell lines with a mean change ≥ 2f o l d
compared to control treatment.
Additional file 2: All probe sets that were analysed in 5 malignant
cell lines following incubation with various concentrations of
Taurolidine (TRD) and Povidon 5% (Pov) as control treatment.
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